バイオマーカーの世界市場：提供別、タイプ別、研究分野別、技術別、疾患別、用途別 - 予測（～2030年）

世界のバイオマーカーの市場規模は、2025年の623億9,000万米ドルから2030年までに1,041億5,000万米ドルに達すると予測され、予測期間にCAGRで10.8%の成長が見込まれます。

市場の成長は、これらのアッセイキットが標準化され最適化されたプロトコルを提供することで、さまざまな生物学的サンプル中のバイオマーカーの正確かつ効率的な分析が容易になり、医療における診断や研究活動に大きく寄与するという利点があるためと考えられます。さらに、ゲノミクス、プロテオミクス、メタボロミクス、次世代シーケンシングなどの技術の進歩により、バイオマーカーの機能が拡大しています。これにより、感度、特異性、予測値が向上した新規バイオマーカーの開発が進んでいます。

「予測バイオマーカーセグメントが2024年に有効性バイオマーカー市場で最大のシェアを占めました。」

2024年、世界のバイオマーカー市場では、予測バイオマーカーセグメントが有効性バイオマーカーセグメントで最大のシェアを占めました。この大きなシェアを支えているのは、予測バイオマーカーに基づく製品が、特定の治療介入から利益を得る可能性がもっとも高い患者を特定することによって、治療の意思決定を導き、臨床転帰を向上できることです。さらに、予測バイオマーカーに関連したコンパニオン診断薬の承認件数が増加していることから、医療現場での採用がさらに強化されています。例えば、PATHWAY anti-HER2/neu（4B5）検査は、trastuzumab deruxtecan（ENHERTU）の投与対象となるHER2低値乳がん患者を同定するもので、2025年1月にHR陽性、HER2陰性転移性乳がんのHER2超低値患者を同定するよう適応拡大されました。

「免疫測定法が2024年にバイオマーカー技術市場で最大のシェアを占めました。」

2024年、免疫測定法がバイオマーカー市場で最大の市場シェアを占めました。これは、その高い特異性と、特に腫瘍、心臓病、感染症などのさまざまな疾患領域にわたってさまざまなバイオマーカーを検出する能力によるものです。スケーラビリティと自動化機能がハイスループット検査をさらに支援し、精密診断に対する需要の高まりに応えています。主要企業は診断サービスを強化するため、イムノアッセイプラットフォームの開発を積極的に進めています。例えば、Rocheはがん診断向けにElecsys Anti-p53イムノアッセイを提供しており、Abbottは感染症検査や慢性疾患モニタリング向けに同社のARCHITECTとAlinityイムノアッセイシステムの拡充を続けています。

「アジア太平洋が予測期間にバイオマーカー市場でもっとも高いCAGRで成長します。」

アジア太平洋が予測期間バイオマーカー市場で最高の成長率を記録すると予測されます。この成長の主な促進要因は、先進の医療検査を受ける患者人口が多いことや、がん治療を改良するための医療政策が支持されていることなどです。さらに、新規薬物療法を開発するための製薬企業やバイオテクノロジー企業による研究活動の活発化も、市場拡大を加速させると予測されます。地域全体で医薬品開発への投資が増加し続けていることから、創薬・開発活動を支援するバイオマーカーの需要も着実に伸びています。

当レポートでは、世界のバイオマーカー市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な調査結果

• バイオマーカー市場の概要
• アジア太平洋のバイオマーカー市場：提供別
• バイオマーカーの市場シェア：エンドユーザー別（2024年）
• バイオマーカー市場：地理的成長機会

第5章 市場の概要

• イントロダクション
• 市場力学
  • 市場促進要因
  • 抑制要因
  • 機会
  • 課題
• 顧客のビジネスに影響を与える動向/混乱
• 規制分析
  • 規制シナリオ
  • 規制機関、政府機関、その他の組織
• バリューチェーン分析
• 技術分析
  • 主要技術
  • 補完技術
  • 隣接技術
• 価格分析
  • アッセイキットの販売価格の動向：主要企業別（2022年～2024年）
  • バイオマーカー消耗品の販売価格の動向：地域別（2024年）
• 特許分析
  • 調査手法
  • 特許出願件数：書類種別（2014年～2025年）
• エコシステム分析
• 主な会議とイベント（2025年～2026年）
• ポーターのファイブフォース分析
• 主なステークホルダーと購入基準
• 投資と資金調達のシナリオ
• 貿易データアナリティクス
  • 輸入シナリオ：HSコード382200（2020年～2024年）
  • 輸出シナリオ：HSコード382200（2020年～2024年）
• バイオマーカー市場に対するAI/生成AIの影響
  • イントロダクション
  • ユースケース
  • バイオマーカーエコシステムにおけるAIの未来
• バイオマーカー市場に対する2025年の米国関税の影響
  • 主な関税率
  • 価格の影響の分析
  • 国・地域に対する影響
  • 最終用途産業に対する影響

第6章 バイオマーカー市場：提供別

• イントロダクション
• 消耗品
  • アッセイキット
  • 試薬・化学品
  • その他の消耗品
• サービス
• ソフトウェア

第7章 バイオマーカー市場：タイプ別

• イントロダクション
• 安全性バイオマーカー
• 有効性バイオマーカー
  • 予測バイオマーカー
  • サロゲートバイオマーカー
  • 薬力学バイオマーカー
  • 予後バイオマーカー
• 検証バイオマーカー

第8章 バイオマーカー市場：研究分野別

• イントロダクション
• ゲノミクス
• プロテオミクス
• メタボロミクス
• その他の研究分野

第9章 バイオマーカー市場：技術別

• イントロダクション
• 免疫アッセイ
  • ELISA
  • タンパク質マイクロアレイ
  • ウェスタンブロッティング
• 次世代シーケンシング（NGS）
• ポリメラーゼ連鎖反応（PCR）
• 質量分析
• クロマトグラフィ
• その他の技術

第10章 バイオマーカー市場：適応疾患別

• イントロダクション
• がん
• 感染症
• 免疫疾患
• 神経疾患
• 心血管疾患
• その他の適応疾患

第11章 バイオマーカー市場：用途別

• イントロダクション
• 臨床診断
• 創薬・医薬品開発
• 個別化医療
• 臨床研究
• その他の用途

第12章 バイオマーカー市場：エンドユーザー別

• イントロダクション
• 製薬・バイオテクノロジー企業
• 病院・診断検査室
• 学術・研究機関
• その他のエンドユーザー

第13章 バイオマーカー市場：地域別

• イントロダクション
• 北米
  • 北米のマクロ経済の見通し
  • 米国
  • カナダ
• 欧州
  • 欧州のマクロ経済の見通し
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • アジア太平洋のマクロ経済の見通し
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • その他のアジア太平洋
• ラテンアメリカ
  • ラテンアメリカのマクロ経済の見通し
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
• 中東
  • 中東のマクロ経済の見通し
  • GCC諸国
  • サウジアラビア
  • アラブ首長国連邦
  • その他のGCC諸国
  • その他の中東
• アフリカ

第14章 競合情勢

• イントロダクション
• 主要参入企業の戦略/強み
• 収益分析（2022年～2024年）
• 市場シェア分析（2024年）
• 企業の評価マトリクス：主要企業（2024年）
• 企業の評価マトリクス：スタートアップ/中小企業（2024年）
• 企業の評価と財務指標
  • 主要企業の評価
  • 主要企業の財務指標
• ブランド/製品の比較分析
• 競合シナリオ

第15章 企業プロファイル

• 主要企業
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • F. HOFFMANN-LA ROCHE LTD.
  • QIAGEN
  • ABBOTT
  • AGILENT TECHNOLOGIES, INC.
  • REVVITY INC.
  • CHARLES RIVER LABORATORIES
  • BIO-RAD LABORATORIES, INC.
  • EUROFINS SCIENTIFIC
  • BIOMERIEUX
  • ILLUMINA, INC.
  • JSR CORPORATION
  • GUARDANT HEALTH
  • LABCORP
  • QUANTERIX
  • MESO SCALE DIAGNOSTICS, LLC
• その他の企業
  • CELERION
  • STANDARD BIOTOOLS
  • SEBIA
  • BIOAGILYTIX LABS
  • STRESSMARQ BIOSCIENCES INC.
  • NORTHEAST BIOANALYTICAL LABORATORIES LLC
  • SIGNOSIS
  • SERIMMUNE
  • THERAINDX LIFESCIENCES PVT. LTD.
  • SYNEXA LIFE SCIENCES BV
  • DIATECH PHARMACOGENETICS
  • SINGULEX, INC.
  • R-BIOPHARM AG

第16章 付録

List of Tables

• TABLE 1 BIOMARKERS MARKET: IMPACT ANALYSIS
• TABLE 2 CANCER INCIDENCE, BY REGION (2040)
• TABLE 3 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, 2022-2024
• TABLE 4 TIMEFRAME FOR BIOMARKER DEVELOPMENT
• TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 9 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024 (USD)
• TABLE 10 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024 (USD)
• TABLE 11 NUMBER OF PATENTS FILED IN BIOMARKERS MARKET, 2014-2025
• TABLE 12 DETAILED ANALYSIS OF KEY PATENTS IN BIOMARKERS MARKET, 2024-2025
• TABLE 13 BIOMARKERS MARKET: ECOSYSTEM
• TABLE 14 BIOMARKERS MARKET: LIST OF CONFERENCES & EVENTS, 2025-2026
• TABLE 15 BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS
• TABLE 17 BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER
• TABLE 18 CANCER BIOMARKER FUNDING BY VARIOUS INSTITUTES/CENTERS IN US, 2021-2024
• TABLE 19 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2020-2024 (USD THOUSAND)
• TABLE 20 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2020-2024 (USD THOUSAND)
• TABLE 21 TABLE 1: US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 22 BIOMARKER PRODUCT-RELATED TARIFF REVISIONS
• TABLE 23 IMPACT ON END-USE APPLICATIONS OF BIOMARKER PRODUCTS
• TABLE 24 BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 25 BIOMARKER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 26 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 27 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 28 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 29 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 30 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 31 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 32 BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 33 BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 34 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 35 EUROPE: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 36 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 37 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 39 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 41 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 42 EUROPE: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 43 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 44 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 45 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 46 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 48 NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 49 EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 50 ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 52 MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 53 GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 BIOMARKER SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 55 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 56 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 57 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 60 GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 BIOMARKER SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 62 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 67 GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 69 SAFETY BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 70 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 75 GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 EFFICACY BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 77 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 81 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 82 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 83 EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 84 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 85 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 87 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 88 LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 90 GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 91 SURROGATE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 92 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 93 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 97 GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 99 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 103 MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 104 GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 106 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 110 MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 111 GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 VALIDATION BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 113 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 115 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 116 LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 117 MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 118 GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 119 BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 120 BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 121 NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 122 EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 123 ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 124 LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 125 MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 126 GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 127 BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 128 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 129 EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 130 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 131 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 132 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 133 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 135 NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 136 EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 137 ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 138 LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 139 MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 140 GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 141 BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 142 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 143 EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 144 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 145 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 146 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 147 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 148 BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 149 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 150 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 151 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 152 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 153 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 154 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 155 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 156 BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 157 BIOMARKERS MARKET FOR ELISA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 158 NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 159 EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 160 ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 161 LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 162 MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 163 GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 164 BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 165 NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 166 EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 167 ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 168 LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 169 MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 170 GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 171 BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 172 NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 173 EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 174 ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 175 LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 176 MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 177 GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 178 BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 179 NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 180 EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 182 LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 183 MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 184 GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2023-2030 (USD MILLION)
• TABLE 185 BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 186 NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 187 EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 188 ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 189 LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 190 MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 191 GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 192 BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 193 NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 194 EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 195 ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 196 LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 197 MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 198 GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 199 BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 200 NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 201 EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 202 ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 203 LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 204 MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 205 GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 206 BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 207 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 208 EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 209 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 210 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 211 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 212 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 213 BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 214 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE
• TABLE 215 BIOMARKERS MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 216 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 217 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 218 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 219 LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 220 MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 221 GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 222 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 223 NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 224 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 225 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 226 LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 227 MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 228 GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 229 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
• TABLE 230 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 231 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 232 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 233 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 234 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 235 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 236 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 237 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 238 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 239 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 240 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 241 LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 242 MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 243 GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 244 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
• TABLE 245 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 246 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 247 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 248 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 249 LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 250 MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 251 GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 252 BIOMARKERS FOR RENAL DISORDERS
• TABLE 253 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 254 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 255 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 256 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 257 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 258 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 259 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 260 BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 261 BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 262 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 263 EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 264 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 265 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 266 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 267 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 268 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 269 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 270 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 271 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 272 LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 273 MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 274 GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 275 LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS
• TABLE 276 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023-2030 (USD MILLION)
• TABLE 277 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 278 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 279 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 280 LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 281 MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023-2030 (USD MILLION)
• TABLE 282 GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 283 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION
• TABLE 284 BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023-2030 (USD MILLION)
• TABLE 285 NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 286 EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 287 ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 288 LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 289 MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023-2030 (USD MILLION)
• TABLE 290 GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 291 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 292 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 293 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 294 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 295 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 296 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 297 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 298 BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 299 PHARMA & BIOTECH SECTOR: RECENT DEVELOPMENTS
• TABLE 300 BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 301 NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 302 EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 303 ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 304 LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 305 MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 306 GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 307 BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 308 NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 309 EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 310 ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 311 LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 312 MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 313 GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 314 BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 315 NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 316 EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 317 ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 318 LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 319 MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 320 GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 321 BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 322 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 323 EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 324 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 325 LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 326 MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 327 GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 328 BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 329 NORTH AMERICA: KEY MACROINDICATORS
• TABLE 330 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 331 NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 332 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 333 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 334 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 335 NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 336 NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 337 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 338 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 339 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 340 NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 341 US: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 342 US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 343 US: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 344 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 345 US: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 346 US: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 347 US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 348 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 349 US: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 350 US: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 351 CANADA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 352 CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 353 CANADA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 354 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 355 CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 356 CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 357 CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 358 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 359 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 360 CANADA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 361 EUROPE: KEY MACROINDICATORS
• TABLE 362 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 363 EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 364 EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 365 EUROPE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 366 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 367 EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 368 EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 369 EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 370 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 371 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 372 EUROPE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 373 GERMANY: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 374 GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 375 GERMANY: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 376 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 377 GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 378 GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 379 GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 380 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 381 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 382 GERMANY: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 383 UK: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 384 UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 385 UK: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 386 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 387 UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 388 UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 389 UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 390 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 391 UK: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 392 UK: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 393 FRANCE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 394 FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 395 FRANCE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 396 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 397 FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 398 FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 399 FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 400 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 401 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 402 FRANCE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 403 ITALY: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 404 ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 405 ITALY: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 406 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 407 ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 408 ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 409 ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 410 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 411 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 412 ITALY: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 413 SPAIN: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 414 SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 415 SPAIN: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 416 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 417 SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 418 SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 419 SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 420 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 421 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 422 SPAIN: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 423 REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 424 REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 425 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 426 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 427 REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 428 REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 429 REST OF EUROPE: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 430 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 431 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 432 REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 433 ASIA PACIFIC: KEY MACROINDICATORS
• TABLE 434 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 435 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 436 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 437 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 438 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 439 ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 440 ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 441 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 442 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 443 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 444 ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 445 CHINA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 446 CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 447 CHINA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 448 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 449 CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 450 CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 451 CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 452 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 453 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 454 CHINA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 455 JAPAN: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 456 JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 457 JAPAN: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 458 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 459 JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 460 JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 461 JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 462 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 463 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 464 JAPAN: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 465 INDIA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 466 INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 467 INDIA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 468 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 469 INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 470 INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 471 INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 472 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 473 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 474 INDIA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 475 SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 476 SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 477 SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 478 SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 479 SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 480 SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 481 SOUTH KOREA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 482 SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 483 SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 484 SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 485 AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 486 AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 487 AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 488 AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 489 AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 490 AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 491 AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 492 AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 493 AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 494 AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 495 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 496 REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 497 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 498 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 499 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 500 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 501 REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 502 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 503 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 504 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 505 LATIN AMERICA: KEY MACROINDICATORS
• TABLE 506 LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 507 LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 508 LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 509 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 510 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 511 LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 512 LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 513 LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 514 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 515 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 516 LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 517 BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 518 BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 519 BRAZIL: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 520 BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 521 BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 522 BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 523 BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 524 BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 525 BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 526 BRAZIL: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 527 MEXICO: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 528 MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 529 MEXICO: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 530 MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 531 MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 532 MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 533 MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 534 MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 535 MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 536 MEXICO: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 537 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 538 REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 539 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 540 REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 541 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 542 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 543 REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 544 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 545 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 546 REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 547 MIDDLE EAST: KEY MACROINDICATORS
• TABLE 548 MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 549 MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 550 MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 551 MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 552 MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 553 MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 554 MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 555 MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 556 MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 557 MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 558 MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 559 GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 560 GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 561 GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 562 GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 563 GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 564 GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 565 GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 566 GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 567 GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 568 GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 569 GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 570 SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 571 SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 572 SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 573 SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 574 SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 575 SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 576 SAUDI ARABIA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 577 SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 578 SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 579 SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 580 UAE: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 581 UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 582 UAE: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 583 UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 584 UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 585 UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 586 UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 587 UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 588 UAE: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 589 UAE: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 590 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 591 REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 592 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 593 REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 594 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 595 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 596 REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 597 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 598 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 599 REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 600 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 601 REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 602 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 603 REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 604 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 605 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 606 REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 607 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 608 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 609 REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 610 AFRICA: KEY MACROINDICATORS
• TABLE 611 AFRICA: BIOMARKERS MARKET, BY OFFERING, 2023-2030 (USD MILLION)
• TABLE 612 AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 613 AFRICA: BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 614 AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 615 AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023-2030 (USD MILLION)
• TABLE 616 AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 617 AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 618 AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023-2030 (USD MILLION)
• TABLE 619 AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 620 AFRICA: BIOMARKERS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 621 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
• TABLE 622 BIOMARKERS MARKET: DEGREE OF COMPETITION
• TABLE 623 BIOMARKERS MARKET: REGION FOOTPRINT
• TABLE 624 BIOMARKERS MARKET: OFFERING FOOTPRINT
• TABLE 625 BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT
• TABLE 626 BIOMARKERS MARKET: APPLICATION FOOTPRINT
• TABLE 627 BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
• TABLE 628 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS
• TABLE 629 BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2025
• TABLE 630 BIOMARKERS MARKET: DEALS, JANUARY 2022-MAY 2025
• TABLE 631 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
• TABLE 632 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
• TABLE 633 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
• TABLE 634 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 635 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 636 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 637 MERCK KGAA: BUSINESS OVERVIEW
• TABLE 638 MERCK KGAA OFFERINGS: PRODUCTS & SERVICES OFFERED
• TABLE 639 MERCK KGAA: DEALS, JANUARY 2022-APRIL 2025
• TABLE 640 MERCK KGAA: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 641 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
• TABLE 642 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
• TABLE 643 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 644 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 645 QIAGEN: BUSINESS OVERVIEW
• TABLE 646 QIAGEN: PRODUCTS & SERVICES OFFERED
• TABLE 647 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 648 QIAGEN: DEALS, JANUARY 2022-APRIL 2025
• TABLE 649 QIAGEN: EXPANSIONS, JANUARY 2022-APRIL 2025
• TABLE 650 ABBOTT: BUSINESS OVERVIEW
• TABLE 651 ABBOTT: PRODUCTS & SERVICES OFFERED
• TABLE 652 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 653 ABBOTT: DEALS, JANUARY 2022-APRIL 2025
• TABLE 654 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
• TABLE 655 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 656 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 657 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 658 REVVITY INC.: BUSINESS OVERVIEW
• TABLE 659 REVVITY INC.: PRODUCTS & SERVICES OFFERED
• TABLE 660 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
• TABLE 661 CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED
• TABLE 662 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022-APRIL 2025
• TABLE 663 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
• TABLE 664 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 665 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 666 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 667 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
• TABLE 668 EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED
• TABLE 669 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022-APRIL 2025
• TABLE 670 BIOMERIEUX: BUSINESS OVERVIEW
• TABLE 671 BIOMERIEUX: PRODUCTS & SERVICES OFFERED
• TABLE 672 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 673 BIOMERIEUX: DEALS, JANUARY 2022-APRIL 2025
• TABLE 674 ILLUMINA, INC.: BUSINESS OVERVIEW
• TABLE 675 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
• TABLE 676 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 677 ILLUMINA, INC.: DEALS, JANUARY 2022-APRIL 2025
• TABLE 678 JSR CORPORATION: BUSINESS OVERVIEW
• TABLE 679 JSR CORPORATION: PRODUCTS & SERVICES OFFERED
• TABLE 680 JSR CORPORATION: DEALS, JANUARY 2022-APRIL 2025
• TABLE 681 GUARDANT HEALTH: BUSINESS OVERVIEW
• TABLE 682 GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED
• TABLE 683 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-APRIL 2025
• TABLE 684 GUARDANT HEALTH: DEALS, JANUARY 2022-APRIL 2025
• TABLE 685 LABCORP: BUSINESS OVERVIEW
• TABLE 686 LABCORP: PRODUCTS & SERVICES OFFERED
• TABLE 687 LABCORP: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 688 QUANTERIX: BUSINESS OVERVIEW
• TABLE 689 QUANTERIX: PRODUCTS & SERVICES OFFERED
• TABLE 690 QUANTERIX: PRODUCT LAUNCHES, JANUARY 2022-APRIL 2025
• TABLE 691 QUANTERIX: DEALS, JANUARY 2022-APRIL 2025
• TABLE 692 MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
• TABLE 693 MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED
• TABLE 694 CELERION: COMPANY OVERVIEW
• TABLE 695 STANDARD BIOTOOLS: COMPANY OVERVIEW
• TABLE 696 SEBIA: COMPANY OVERVIEW
• TABLE 697 BIOAGILYTIX LABS: COMPANY OVERVIEW
• TABLE 698 STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW
• TABLE 699 NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW
• TABLE 700 SIGNOSIS: BUSINESS OVERVIEW
• TABLE 701 SERIMMUNE: BUSINESS OVERVIEW
• TABLE 702 THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW
• TABLE 703 SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW
• TABLE 704 DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW
• TABLE 705 SINGULEX, INC.: BUSINESS OVERVIEW
• TABLE 706 R-BIOPHARM AG: BUSINESS OVERVIEW

List of Figures

• FIGURE 1 RESEARCH DESIGN
• FIGURE 2 BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
• FIGURE 3 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
• FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
• FIGURE 5 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2024)
• FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 8 BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
• FIGURE 9 BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 BIOMARKERS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
• FIGURE 12 BIOMARKERS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 BIOMARKERS MARKET, BY RESEARCH AREA, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 BIOMARKERS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 BIOMARKERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET
• FIGURE 17 GROWING PIPELINE OF PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
• FIGURE 18 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF BIOMARKERS MARKET IN ASIA PACIFIC IN 2024
• FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 20 CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL BIOMARKERS MARKET DURING FORECAST PERIOD
• FIGURE 21 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 23 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 24 AVERAGE SELLING PRICE OF ASSAY KITS, BY KEY PLAYER, 2022-2024 (USD)
• FIGURE 25 PATENT ANALYSIS OF BIOMARKERS MARKET, JANUARY 2014-MAY 2025
• FIGURE 26 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 27 BIOMARKERS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS
• FIGURE 29 KEY BUYING CRITERIA FOR END USERS
• FIGURE 30 IMPACT OF AI ON BIOMARKER ECOSYSTEM
• FIGURE 31 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
• FIGURE 32 ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT
• FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2022-2024 (USD MILLION)
• FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2024
• FIGURE 35 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 36 BIOMARKERS MARKET: COMPANY FOOTPRINT
• FIGURE 37 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 38 EV/EBITDA OF KEY VENDORS
• FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 40 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
• FIGURE 41 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
• FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2024)
• FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2024)
• FIGURE 45 ABBOTT: COMPANY SNAPSHOT (2024)
• FIGURE 46 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 47 REVVITY INC.: COMPANY SNAPSHOT (2024)
• FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
• FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 50 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
• FIGURE 51 BIOMERIEUX: COMPANY SNAPSHOT (2024)
• FIGURE 52 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 53 JSR CORPORATION: COMPANY SNAPSHOT (2023)
• FIGURE 54 GUARDANT HEALTH: COMPANY SNAPSHOT (2024)
• FIGURE 55 LABCORP: COMPANY SNAPSHOT (2024)
• FIGURE 56 QUANTERIX: COMPANY SNAPSHOT (2024)

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The growth of this market can be attributed to the advantage that these assay kits offer standardized and optimized protocols, facilitating accurate and efficient analysis of biomarkers in various biological samples, thus contributing significantly to diagnostic and research endeavors in healthcare. Further, advances in technologies such as genomics, proteomics, metabolomics, and next-generation sequencing have expanded the capabilities of biomarkers. This has led to the development of novel biomarkers with enhanced sensitivity, specificity, and predictive value.

"The predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market in 2024."

The market by type is segmented into safety, efficacy, and validation biomarkers. Efficacy biomarkers are further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers segment in the global biomarkers market. This large share is supported by the ability of predictive biomarker-based offerings to guide treatment decisions and improve clinical outcomes by identifying patients most likely to benefit from a particular therapeutic intervention, which is especially valuable in oncology, autoimmune disorders, and infectious diseases. Moreover, the growing number of companion diagnostic approvals linked to predictive biomarkers further reinforced their adoption across healthcare settings. For instance, Roche's PATHWAY anti-HER2/neu (4B5) test identifies HER2-low breast cancer patients eligible for trastuzumab deruxtecan (ENHERTU), which received a label expansion in January 2025 to identify HER2-ultralow patients in HR-positive, HER2-negative metastatic breast cancer.

"Immunoassays held the largest share in the biomarker technologies market in 2024."

The biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. In 2024, immunoassays held the largest market share in the biomarkers market due to their high specificity and ability to detect various biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases. Scalability and automation capabilities further support high-throughput testing, meeting the rising demand for precision diagnostics. Major companies are actively advancing immunoassay platforms to enhance their diagnostic offerings. For instance, Roche offers the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott continues to expand its ARCHITECT and Alinity immunoassay systems for infectious disease testing and chronic condition monitoring.

"The Asia Pacific region is growing at the highest CAGR in the biomarkers market during the forecast period."

The Asia Pacific is projected to register the highest growth rate in the biomarkers market during the forecast period. Key drivers of this growth include a large patient population undergoing advanced medical testing and supportive healthcare policies to improve cancer care. Additionally, increased research activity by pharmaceutical and biotechnology companies to develop novel drug therapies is expected to accelerate market expansion. As investment in drug development continues to rise across the region, the demand for biomarkers that support drug discovery and development efforts is growing steadily.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), and Laboratory Corporation of America Holdings (US) are some of the key players in the biomarkers market.

The study includes an in-depth competitive analysis of these key players in the biomarkers market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the biomarkers market by offering [consumables (assay kits, columns & filters, reagents & chemicals), services, and software], type (safety biomarkers, efficacy biomarkers (surrogate biomarkers, pharmacodynamics biomarkers, predictive biomarkers, and prognostic biomarkers), and validation biomarkers), research area (genomics, proteomics, metabolomics, and other research area), technology [immunoassays (western blot, ELISA, and protein microarray), NGS, PCR, mass spectrometry, chromatography, and other technologies], disease indication (cancer, infectious diseases, cardiovascular disorders, immunological disorders, neurological disorders, and other disease indications), application (clinical diagnostics, drug discovery & development, personalized medicines, clinical research, and other applications), end user (pharmaceutical & biotechnologies companies, hospitals & diagnostics laboratories, research & academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the biomarkers market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (increasing use of biomarkers in drug discovery & development, growing importance of companion diagnostics, rising prevalence of cancer, developments of biomarkers for rare diseases, increasing funds and grants for biomarker research, advancement in omics technologies), restraints (high capital investments and extensive timelines for biomarker development, disease complexity, and heterogeneity), opportunities (growing preference for personalized medicine and precision oncology, enhanced collaboration among healthcare providers and key industry players, high growth potential of emerging economies), and challenges (issues associated with quantification and validation of biomarkers, complexities associated with data set integration, technical issues related to sample collection and storage) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the biomarkers market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the biomarkers market
• Competitive Assessment: In-depth assessment of market share, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), QIAGEN (Netherlands), Revvity (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Eurofins Scientific (Luxembourg), BIOMERIEUX (France), Agilent Technologies, Inc. (US), JSR Corporation (Japan), and Quanterix (US), among others, in the biomarkers market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 STUDY SCOPE
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOMARKERS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING
• 4.3 BIOMARKERS MARKET SHARE, BY END USER, 2024
• 4.4 BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 MARKET DRIVERS
    • 5.2.1.1 Increasing use of biomarkers in drug discovery & development
    • 5.2.1.2 Growing importance of companion diagnostics
    • 5.2.1.3 Rising prevalence of cancer
    • 5.2.1.4 Development of biomarkers for rare diseases
    • 5.2.1.5 Increasing funds and grants for biomarker research
    • 5.2.1.6 Advancement in omics technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High capital investments and extensive timelines for biomarker development
    • 5.2.2.2 Disease complexity and heterogeneity
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for personalized medicine and precision oncology
    • 5.2.3.2 Enhanced collaboration among healthcare providers and key industry players
    • 5.2.3.3 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with quantification & validation of biomarkers
    • 5.2.4.2 Complexities associated with data set integration
    • 5.2.4.3 Technical issues related to sample collection and storage
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY ANALYSIS
  • 5.4.1 REGULATORY SCENARIO
    • 5.4.1.1 US
    • 5.4.1.2 Europe
    • 5.4.1.3 Asia Pacific
    • 5.4.1.4 Rest of the World
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGICAL ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Immunoassays
      • 5.6.1.1.1 Immunohistochemistry (IHC)
      • 5.6.1.1.2 ELISA
    • 5.6.1.2 Next-generation Sequencing (NGS)
    • 5.6.1.3 Polymerase chain reaction (PCR)
    • 5.6.1.4 In situ hybridization
    • 5.6.1.5 Microarrays
    • 5.6.1.6 Mass Spectrometry
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Liquid biopsy
    • 5.6.2.2 CRISPR
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Artificial intelligence (AI) and machine learning (ML)
    • 5.6.3.2 Sensors (wearable devices)
• 5.7 PRICING ANALYSIS
  • 5.7.1 INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022-2024
  • 5.7.2 INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024
• 5.8 PATENT ANALYSIS
  • 5.8.1 METHODOLOGY
  • 5.8.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2025
• 5.9 ECOSYSTEM ANALYSIS
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 THREAT OF NEW ENTRANTS
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BIOMARKERS MARKET: BUYING CRITERIA
• 5.13 INVESTMENT & FUNDING SCENARIO
• 5.14 TRADE DATA ANALYSIS
  • 5.14.1 IMPORT SCENARIO: HS CODE 382200, 2020-2024
  • 5.14.2 EXPORT SCENARIO: HS CODE 382200, 2020-2024
• 5.15 IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 USE CASES
  • 5.15.3 FUTURE OF AI IN BIOMARKER ECOSYSTEM
• 5.16 IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET
  • 5.16.1 KEY TARIFF RATES
  • 5.16.2 PRICE IMPACT ANALYSIS
  • 5.16.3 IMPACT ON COUNTRIES/REGIONS
    • 5.16.3.1 US
    • 5.16.3.2 Europe
    • 5.16.3.3 Asia Pacific
  • 5.16.4 IMPACT ON END-USE INDUSTRIES
    • 5.16.4.1 Pharmaceutical & biotech companies
    • 5.16.4.2 Hospitals & diagnostic laboratories
    • 5.16.4.3 Contract research organizations

6 BIOMARKERS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 ASSAY KITS
    • 6.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
  • 6.2.2 REAGENTS & CHEMICALS
    • 6.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand
  • 6.2.3 OTHER CONSUMABLES
• 6.3 SERVICES
  • 6.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
• 6.4 SOFTWARE
  • 6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

7 BIOMARKERS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 SAFETY BIOMARKERS
  • 7.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH
• 7.3 EFFICACY BIOMARKERS
  • 7.3.1 PREDICTIVE BIOMARKERS
    • 7.3.1.1 Rising applications of biomarkers in personalized medicine to drive market
  • 7.3.2 SURROGATE BIOMARKERS
    • 7.3.2.1 Ability to serve as reliable indicator in place of clinical endpoints to support market growth
  • 7.3.3 PHARMACODYNAMIC BIOMARKERS
    • 7.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
  • 7.3.4 PROGNOSTIC BIOMARKERS
    • 7.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers
• 7.4 VALIDATION BIOMARKERS
  • 7.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

8 BIOMARKERS MARKET, BY RESEARCH AREA

• 8.1 INTRODUCTION
• 8.2 GENOMICS
  • 8.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
• 8.3 PROTEOMICS
  • 8.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
• 8.4 METABOLOMICS
  • 8.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
• 8.5 OTHER RESEARCH AREAS

9 BIOMARKERS MARKET, BY TECHNOLOGY

• 9.1 INTRODUCTION
• 9.2 IMMUNOASSAYS
  • 9.2.1 ELISA
    • 9.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth
  • 9.2.2 PROTEIN MICROARRAYS
    • 9.2.2.1 Quick and cost-effective nature of technology to support growth
  • 9.2.3 WESTERN BLOT
    • 9.2.3.1 Increasing investments in proteomics research to drive market
• 9.3 NEXT-GENERATION SEQUENCING (NGS)
  • 9.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
• 9.4 POLYMERASE CHAIN REACTION (PCR)
  • 9.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
• 9.5 MASS SPECTROMETRY
  • 9.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH
• 9.6 CHROMATOGRAPHY
  • 9.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
• 9.7 OTHER TECHNOLOGIES

10 BIOMARKERS MARKET, BY DISEASE INDICATION

• 10.1 INTRODUCTION
• 10.2 CANCER
  • 10.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET
• 10.3 INFECTIOUS DISEASES
  • 10.3.1 INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND
• 10.4 IMMUNOLOGICAL DISORDERS
  • 10.4.1 RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET
• 10.5 NEUROLOGICAL DISORDERS
  • 10.5.1 WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH
• 10.6 CARDIOVASCULAR DISORDERS
  • 10.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS
• 10.7 OTHER DISEASE INDICATIONS

11 BIOMARKERS MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 CLINICAL DIAGNOSTICS
  • 11.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
• 11.3 DRUG DISCOVERY & DEVELOPMENT
  • 11.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
• 11.4 PERSONALIZED MEDICINE
  • 11.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
• 11.5 CLINICAL RESEARCH
  • 11.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
• 11.6 OTHER APPLICATIONS

12 BIOMARKERS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES
  • 12.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
• 12.3 HOSPITALS & DIAGNOSTIC LABORATORIES
  • 12.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
• 12.4 ACADEMIC & RESEARCH INSTITUTES
  • 12.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
• 12.5 OTHER END USERS

13 BIOMARKERS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 Rising focus on biopharma research to support growth
  • 13.2.3 CANADA
    • 13.2.3.1 Increasing incidence of cancer to drive biomarkers market growth
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Growth in biopharmaceutical R&D activities to propel growth
  • 13.3.3 UK
    • 13.3.3.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
  • 13.3.4 FRANCE
    • 13.3.4.1 Increasing government investment for proteomics & genomics research to drive growth
  • 13.3.5 ITALY
    • 13.3.5.1 Increasing developments in life science research to fuel growth
  • 13.3.6 SPAIN
    • 13.3.6.1 R&D initiatives for personalized medicine to support market growth
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Rising incidence of CVD to propel market
  • 13.4.3 JAPAN
    • 13.4.3.1 Strong regulatory guidelines for drug discovery & development to support market growth
  • 13.4.4 INDIA
    • 13.4.4.1 Favorable scenario for FDI and increasing number of clinical trials to propel market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Increasing innovations in NGS technologies to support market growth
  • 13.4.6 AUSTRALIA
    • 13.4.6.1 Increasing demand for diagnostic solutions to propel market
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Increased government investments in pharmaceutical R&D to drive market
  • 13.5.3 MEXICO
    • 13.5.3.1 Rising demand for chronic disease treatment to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 13.6.2 GCC COUNTRIES
  • 13.6.3 SAUDI ARABIA
    • 13.6.3.1 Growing healthcare expenditure to boost market growth
  • 13.6.4 UAE
    • 13.6.4.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth
  • 13.6.5 REST OF GCC COUNTRIES
    • 13.6.5.1 Other GCC countries include Bahrain, Kuwait, Oman, and Qatar.
  • 13.6.6 REST OF MIDDLE EAST
    • 13.6.6.1 The Rest of the Middle East includes Egypt, Turkey, Iran, and Iraq.
• 13.7 AFRICA
  • 13.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
  • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET
• 14.3 REVENUE ANALYSIS, 2022-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Offering footprint
    • 14.5.5.4 Technology footprint
    • 14.5.5.5 Application footprint
• 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of key startups/SMEs
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 VALUATION OF KEY PLAYERS
  • 14.7.2 FINANCIAL METRICS OF KEY PLAYERS
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 14.8.1 BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 THERMO FISHER SCIENTIFIC INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products & services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches & approvals
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 MERCK KGAA
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products & services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
      • 15.1.2.3.2 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products & services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches & approvals
      • 15.1.3.3.2 Deals
  • 15.1.4 QIAGEN
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products & services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches & approvals
      • 15.1.4.3.2 Deals
      • 15.1.4.3.3 Expansions
  • 15.1.5 ABBOTT
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products & services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches & approvals
      • 15.1.5.3.2 Deals
  • 15.1.6 AGILENT TECHNOLOGIES, INC.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products & services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product launches & approvals
      • 15.1.6.3.2 Deals
  • 15.1.7 REVVITY INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products & services offered
  • 15.1.8 CHARLES RIVER LABORATORIES
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products & services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 BIO-RAD LABORATORIES, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products & services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product launches
      • 15.1.9.3.2 Deals
  • 15.1.10 EUROFINS SCIENTIFIC
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products & services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Deals
  • 15.1.11 BIOMERIEUX
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products & services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches & approvals
      • 15.1.11.3.2 Deals
  • 15.1.12 ILLUMINA, INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products & services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches & approvals
      • 15.1.12.3.2 Deals
  • 15.1.13 JSR CORPORATION
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products & services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Deals
  • 15.1.14 GUARDANT HEALTH
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products & services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches & approvals
      • 15.1.14.3.2 Deals
  • 15.1.15 LABCORP
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products & services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Product launches
  • 15.1.16 QUANTERIX
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products & services offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Product launches
      • 15.1.16.3.2 Deals
  • 15.1.17 MESO SCALE DIAGNOSTICS, LLC
    • 15.1.17.1 Business overview
    • 15.1.17.2 Products & services offered
• 15.2 OTHER PLAYERS
  • 15.2.1 CELERION
  • 15.2.2 STANDARD BIOTOOLS
  • 15.2.3 SEBIA
  • 15.2.4 BIOAGILYTIX LABS
  • 15.2.5 STRESSMARQ BIOSCIENCES INC.
  • 15.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC
  • 15.2.7 SIGNOSIS
  • 15.2.8 SERIMMUNE
  • 15.2.9 THERAINDX LIFESCIENCES PVT. LTD.
  • 15.2.10 SYNEXA LIFE SCIENCES BV
  • 15.2.11 DIATECH PHARMACOGENETICS
  • 15.2.12 SINGULEX, INC.
  • 15.2.13 R-BIOPHARM AG

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS